Link to Full Article MARINA DEL REY, Calif., Oct. 29, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today issued the following letter to shareholders. The letter has been made available to all existing shareholders with the Proxy for the […]
Link to Full Article A recent study from the University of Birmingham has shown that the Congenica platform demonstrated superior performance in identifying the genetic causes of platelet-related bleeding disorders [1]. Whole Exome Sequencing in combination with deep platelet phenotyping has been used in an earlier study (Genotyping and Phenotyping of Platelets, UK-GAPP) to identify pathogenic genetic […]
Link to Full Article Appointment adds extensive expertise in the development of anti-infectives, including bacteriophage therapy to treat P. aeruginosa infections in cystic fibrosis patients MARINA DEL REY, Calif., Oct. 26, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat […]
Link to Full Article FundamentalVR launches full commercial ophthalmology capability BOSTON – October 20, 2020 – FundamentalVR, global pioneers in immersive VR surgical skills training and skills data analytics, today announced the expansion of its surgical specialty capabilities with the addition of ophthalmology. Powered the company’s patented HapticVRTM technology architecture that mimics the physical cues of […]
Link to Full Article Adds ready-to-administer injectable product to companies’ existing partnership London and Cambridge, October 20, 2020 – Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into a new exclusive agreement to co-develop […]
Link to Full Article Upcoming study, to be known as “SWARM-P.a.,” is believed to be first FDA cleared, controlled clinical trial to evaluate a multiple phage-based mixture as a therapeutic candidate in Cystic Fibrosis patients MARINA DEL REY, Calif., Oct. 15, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused […]
Link to Full Article 101 patients recruited in Phase 2b clinical study of lead asset XF-73 for the prevention of postsurgical infections Recruitment on track to complete year-end and report results in Q1 2021 Brighton, United Kingdom – 12 October 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the […]
Link to Full Article Cambridge, United Kingdom – 22 September 2020 – Congenica has launched a new module for its genomic analysis platform that will accelerate research into the relationship between an individual’s genomic variation and COVID-19 susceptibility, severity, and clinical outcomes. Since the beginning of the COVID-19 global pandemic outbreak, the global research community has united in an unprecedented effort […]
Link to Full Article Silicon Valley heavy hitter brings decades of experience founding and growing over 70 Medtech companies to FundamentalVR to continue scaling its immersive surgical simulation platform. LONDON – September 22, 2020 – FundamentalVR, global leaders in using immersive technology to improve the way surgeons are trained, announces Allan May as Chairman of the […]
Link to Full Article Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical infections Recruitment on track to complete year-end and report results in early 2021 Brighton, United Kingdom – 17 September 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: